¿ªÔÆÌåÓý

18 years - VISION and IVY Networks, September 2024-January 2025. 

MMWR: Morbidity and Mortality Weekly Report. 2025

Influenza-associated hospitalization rates by underlying conditions, 2016-17 to 2019-20: a retrospective cohort study. 

Journal of Infectious Diseases. 2025

Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness - four vaccine effectiveness networks, United States, October 2024-February 2025. 

MMWR: Morbidity and Mortality Weekly Report. 2025

Patterns in prescribing and dispensing of influenza antivirals among adults with influenza presenting to urgent care and emergency department settings, VISION Network, 2023-2024. 

Clinical Infectious Diseases. 2025

Vaccination during pregnancy in the Vaccine Safety Datalink, 2002-2022. 

Pediatric Infectious Disease Journal. 2025

18 Years - VISION and IVY Networks, September 2023-January 2024. 

MMWR: Morbidity and Mortality Weekly Report. 2024

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 

Clinical Infectious Diseases. 2024

Coronavirus disease 2019 (COVID-19) vaccination and stillbirth in the Vaccine Safety Datalink. 

Obstetrics and Gynecology. 2024

Effectiveness of the original monovalent and bivalent COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters in pregnant persons who were not immunocompromised: VISION Network, June 2022-August 2023. 

Open forum infectious diseases. 2024

Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States. 

Clinical Infectious Diseases. 2024

Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 

Journal of Infectious Diseases. 2024

Lack of evidence for vaccine-associated enhanced disease from COVID-19 vaccines among adults in the Vaccine Safety Datalink. 

Pharmacoepidemiology and Drug Safety. 2024

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 

Lancet (London, England). 2024

Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 

Influenza and other respiratory viruses. 2024

Safety of the seasonal influenza vaccine in 2 successive pregnancies. 

JAMA network open. 2024

Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 

Clinical Infectious Diseases. 2024

Accuracy of COVID-19-like illness diagnoses in electronic health record data: retrospective cohort study. 

JMIR formative research. 2023

Association between aluminum exposure from vaccines before age 24 months and persistent asthma at age 24 to 59 months. 

Academic Pediatrics. 2023

COVID-19 booster vaccination in early pregnancy and surveillance for spontaneous abortion. 

JAMA network open. 2023

COVID-19 vaccine safety surveillance in early pregnancy in the United States: design factors affecting the association between vaccine and spontaneous abortion. 

American Journal of Epidemiology. 2023

Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 

Pediatrics. 2023

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 

Vaccine. 2023

Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 

American Journal of Transplantation. 2023

Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 

JAMA network open. 2023

Influenza vaccination among pregnant people before and during the coronavirus disease 2019 (COVID-19) pandemic. 

Obstetrics and Gynecology. 2023

Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons. 

Vaccine. 2023

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. 

Lancet Reg Health Am. 2023

Patient and epidemiological factors associated with influenza testing in hospitalized adults with acute respiratory illnesses, 2016-2017 to 2019-2020. 

Open forum infectious diseases. 2023

Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance. 

Journal of Infectious Diseases. 2023

Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 

Journal of Infectious Diseases. 2023

Relationships between social vulnerability and coronavirus disease 2019 vaccination coverage and vaccine effectiveness. 

Clinical Infectious Diseases. 2023

Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. 

Vaccine. 2023

Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. 

Vaccine. 2023

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 

Journal of Infectious Diseases. 2023

Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 

American Journal of Transplantation. 2022

Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 

JAMA network open. 2022

Monitoring vaccine safety using the Vaccine Safety Datalink: assessing capacity to integrate data from Immunization Information systems. 

Vaccine. 2022

Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth - eight integrated health care organizations, United States, December 15, 2020-July 22, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Relative risks of COVID-19-associated hospitalizations and clinical outcomes by age and race/ethnicity-March 2020-March 2021. 

Open forum infectious diseases. 2022

Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 

BMJ (Clinical research ed.). 2022

COVID-19 vaccination coverage among pregnant women during pregnancy - eight integrated health care organizations, United States, December 14, 2020-May 8, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Developing algorithms for identifying major structural birth defects using automated electronic health data. 

Pharmacoepidemiology and Drug Safety. 2021

Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 

New England Journal of Medicine. 2021

Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. 

Vaccine. 2021

Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. 

Therapeutic advances in drug safety. 2021

Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study. 

Vaccine. 2019

2015-2016 Vaccine effectiveness of live attenuated and inactivated influenza vaccines in children in the United States. 

Clinical Infectious Diseases. 2018

Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. 

Pharmacoepidemiology and Drug Safety. 2018

Uptake and safety of Hepatitis B vaccination during pregnancy: a Vaccine Safety Datalink study. 

Vaccine. 2018

Risk of anaphylaxis after vaccination in children and adults. 

Journal of Allergy and Clinical Immunology. 2016

Vaccinations given during pregnancy, 2002-2009: a descriptive study. 

American Journal of Preventive Medicine. 2014

Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. 

Vaccine. 2013

Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010. 

Pharmacoepidemiology and Drug Safety. 2013

Trivalent inactivated influenza vaccine and spontaneous abortion. 

Obstetrics and Gynecology. 2013

Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. 

Influenza and other respiratory viruses. 2012

H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. 

American Journal of Preventive Medicine. 2011

Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. 

Pediatric Infectious Disease Journal. 2010